Regulatory May 9, 2025

Lipidor AB (publ) publishes annual report for 2024

STOCKHOLM, Sweden, 9th May 2025 – Today, Lipidor AB (publ) (Nasdaq First North Growth Market: LIPI) publishes its annual report for the financial year 2024. The report is available on the company's website lipidor.se and in the attached pdf (in Swedish).

To read the report in full (in Swedish) click here: https://lipidor.se/investors/financial-reports/

The information was provided for publication by Lipidor’s CEO on 9th May 2025 at 2.25pm (CEST).

For more information, please contact
Lipidor AB (Reg. No. 556779-7500)
Ola Holmlund, CEO
Phone: +46 725 07 03 69
E-mail: ola.holmlund@lipidor.se
c/o Ekonomistubben
Box 55931
102 16 Stockholm

Certified adviser
The company’s Certified Adviser is Carnegie Investment Bank AB (publ)
Phone: +46 738 56 42 65
Email: certifiedadviser@carnegie.se

About Lipidor AB
Lipidor AB (Nasdaq First North Growth Market: LIPI) (www.lipidor.se) is a pharmaceutical development company with a pipeline of pharmaceutical development projects in preclinical and clinical phases. The company can develop topical medical products for the treatment of diseases such as psoriasis, acne vulgaris, bacterial skin infections and atopic dermatitis by reformulation of proven pharmaceutical substances. Lipidor’s priority project is AKP02G2, which focusses on psoriasis.

Attachments
Annual Report (Swedish) 2024

Annual Report (Swedish) 2024